Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PAPILOBS GR: A Clinical Investigation to Assess the Effectiveness of PAPILOCARE® in the Regression of Cervix Cytological Abnormalities Caused by HPV.

NCT06399341 is registered in ClinicalTrials.gov with Elpen Pharmaceutical Co. Inc. as lead sponsor.

NCT NCT06399341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06399341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PAPILOBS GR: A Clinical Investigation to Assess the Effectiveness of PAPILOCARE® in the Regression of Cervix Cytological Abnormalities Caused by HPV.
Lead sponsor
Elpen Pharmaceutical Co. Inc.
Phase
Observational
Overall status
Completed
Start date
September 1, 2021
Completion date
April 30, 2023
Enrollment
524 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

papillomavirus infections